The curtains have risen on DCAT 2024 in the vibrant heart of New York City, and leading pharmaceutical companies from around the world have converged for a week of innovation, collaboration, and strategic dialogue.
Experts from global professional services outfit Alvarez and Marsal outline challenges created or exacerbated by COVID-19 and insights into potential solutions.
Outsourcing-Pharma recently conducted a second ‘state of the industry’ survey to gauge views about the current state of the global pharmaceutical outsourcing market and the evolving relationships of those involved.
The pharma industry must fight “vendor indifference” so suppliers and services companies are not prey to cyber attacks that can lose drug companies hundreds of thousands of dollars in minutes, according to US Homeland Security’s former head of cybercrimes...
The SEC’s enforcement director is calling out pharma companies for failing to disclose and misinforming investors about correspondence with the US FDA.
Draft guidance distinguishing wearable medical devices from ‘general wellness’ devices could slow pharma’s adoption of such data in the short-term, according to an analyst.
Sounding upbeat on Covance’s recent gains in its early stage clinical business, CFO Alison Cornell expressed a conservative amount of optimism that growth will continue.
DKSH has upgraded its cold chain infrastructure in Southeast Asia as both small and large manufacturers increase their access needs to emerging markets.
Vindon says its investments in its Irish and Californian facilities come as pharma companies shift to outsourcing stability storage in order to save costs.
The recent wave of M&A will lead to manufacturing over-capacity at pharma companies but only a small number of these sites will be sold to CMOs, in part because of the facilities’ suboptimal locations, according to a report.
There has been “tremendous interest” in Fate Therapeutics’ Catalyst programme, which gives access to induced iPS cell technology as part of collaborative relationship between numerous companies.
Despite the challenges that emerging market present, such as
intellectual property (IP) exposure and drug pricing controls, the
pharma industry is not being deterred.
The demand for international assistance in recruitment processes
from pharmaceutical companies is set to boom in the next 12 months,
according to an industry player.
The US Food and Drug Administration (FDA) and the pharmaceutical
industry are in strong negotiations to decide how much drug
companies will pay the agency to review new drugs from the end of
next year, when the current law expires.
Outsourcing-Pharma.com focus on: cutting the cost of clinical trials
Outsourcing-Pharma.com sheds some light on how pharma companies can
make sure they are choosing a contract research organisations (CRO)
that will stick to the rules of ethics when running clinical trials
in poorly-regulated countries...
IT services company HCL Technologies continues to experience rapid
growth through its ability to undercut clinical research
organisations (CROs) on price for clinical data management (CDM)
services through its new operations in India.
Glemser Technologies has released a new version of its labelling
software, designed to reduce the costs, complexity and regulatory
risk involved with producing pharma product inserts.
2005 was a challenging year for contract sales organisations (CSO),
with many downsizing their sales teams. However, In2Focus, is
bucking the industry trend, and increasing its headcount to meet
demand.
In order to stay competitive, Wyeth looks to model its business not
on that of other pharma companies, but of other successful big
industries, which includes outsourcing or off-shoring anything that
is not a core function.
A new report into pharmaceutical R&D has identified an emerging
trend favouring outsourcing of discovery research, clinical trials
and formulation manufacturing, providing pressure relief from
consistent, high-growth financial...
